Key facts
- It has raised $116.1M; the latest was Debt - General ($32.0M) in Nov 2024.
- Notable investors include Bpifrance, La French Tech, XAnge, BNP Paribas Développement, IRDI Capital Investissement — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Treefrog Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Treefrog Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Treefrog Therapeutics
Developer of a proprietary technology platform designed to provide alternative access to cell therapies. The company's tool provides an end-to-end three-dimensional scalable service that will reduce treatment costs as well as help cell therapy players secure cell production and quality, fasten clinical development, and facilitate market access, enabling patients to access safe and affordable stem cell therapy.
- Sector
- Healthcare
- HQ
- Pessac, France
- Founded
- 2018
- Employees
- 177
- Website
- treefrog.fr/
- Ownership
- Privately Held (backing)
Treefrog Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Treefrog Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Treefrog Therapeutics in its N-PORT filings yet. We sweep new filings monthly.